Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 SEK | -4.40% | +17.56% | +27.88% |
05-23 | Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy | CI |
05-21 | Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+27.88% | 88.17M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- CANTA Stock
- News Cantargia AB
- Cantargia AB Announces Executive Changes